It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Fibroblasts are the main cells of connective tissue and have pivotal roles in the proliferative and maturation phases of wound healing. These cells can secrete various cytokines, growth factors, and collagen. Vascular endothelial growth factor (VEGF) is a unique factor in the migration process of fibroblast cells through induces wound healing cascade components such as angiogenesis, collagen deposition, and epithelialization. This study aimed to create VEGF165 overexpressing fibroblast cells to evaluate angiogenesis function in wound healing. In vitro, a novel recombinant expression vector, pcDNA3.1(-)-VEGF, was produced and transfected into the fibroblast cells. Following selecting fibroblast cells with hygromycin, recombinant cells were investigated in terms of VEGF expression by quantifying and qualifying methods. Mechanical, physical, and survival properties of polyurethane-cellulose acetate (PU-CA) scaffold were investigated. Finally, in vivo, the angiogenic potential was evaluated in four groups containing control, PU-CA, PU-CA with fibroblast cells, and VEGF-expressing cells on days 0, 2, 5, 12 and 15. Wound biopsies were harvested and the healing process was histopathologically evaluated on different days. qRT-PCR showed VEGF overexpression (sevenfold) in genetically-manipulated cells compared to fibroblast cells. Recombinant VEGF expression was also confirmed by western blotting. Manipulated fibroblast cells represented more angiogenesis than other groups on the second day after surgery, which was also confirmed by the antiCD31 antibody. The percentage of wound closure area on day 5 in genetically-manipulated Hu02 and Hu02 groups showed a significant reduction of wound area compared to other groups. These findings indicate that overexpression of VEGF165 in fibroblast cells results in enhanced angiogenesis and formation of granulated tissue in the early stage of the healing process, which can show its therapeutic potential in patients with impaired wound healing and also provide functional support for gene therapy.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Shahid Beheshti University of Medical Sciences, Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Tehran, Iran (GRID:grid.411600.2)
2 Shahid Beheshti University of Medical Sciences, Skin Research Center, Tehran, Iran (GRID:grid.411600.2)
3 Shahid Beheshti University of Medical Sciences, Medical Nanotechnology and Tissue Engineering Research Center, Tehran, Iran (GRID:grid.411600.2); Shahid Beheshti University of Medical Sciences, Department of Tissue Engineering and Applied Cell Sciences, School of Advanced Technologies in Medicine, Tehran, Iran (GRID:grid.411600.2)
4 Stanford University School of Medicine, Stanford Cardiovascular Institute, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956); Stanford University School of Medicine, Department of Medicine, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956)
5 Shahid Beheshti University of Medical Sciences, Department of Tissue Engineering and Applied Cell Sciences, School of Advanced Technologies in Medicine, Tehran, Iran (GRID:grid.411600.2); Tarbiat Modares University, Department of Molecular Genetics, Faculty of Biological Sciences, Tehran, Iran (GRID:grid.412266.5) (ISNI:0000 0001 1781 3962)
6 Shahid Beheshti University, Department of Animal Sciences and Biotechnology, Faculty of Life Sciences and Biotechnology, Tehran, Iran (GRID:grid.412502.0) (ISNI:0000 0001 0686 4748)
7 University of Tehran, Department of Clinical Pathology, Faculty of Veterinary Medicine, Tehran, Iran (GRID:grid.46072.37) (ISNI:0000 0004 0612 7950)